Top

Journal of Cardiovascular Translational Research

31-01-2024 | Epigenetics | Review

Therapeutic Strategies for Angiogenesis Based on Endothelial Cell Epigenetics

Authors: Yue Cai, Lihua Li, Chen Shao, Yiliu Chen, Zhongqun Wang

Published in: Journal of Cardiovascular Translational Research

Abstract

With the in-depth investigation of various diseases, angiogenesis has gained increasing attention. Among the contributing factors to angiogenesis research, endothelial epigenetics has emerged as an influential player. Endothelial epigenetic therapy exerts its regulatory effects on endothelial cells by controlling gene expression, RNA, and histone modification within these cells, which subsequently promotes or inhibits angiogenesis. As a result, this therapeutic approach offers potential strategies for disease treatment. The purpose of this review is to outline the pertinent mechanisms of endothelial cell epigenetics, encompassing glycolysis, lactation, amino acid metabolism, non-coding RNA, DNA methylation, histone modification, and their connections to specific diseases and clinical applications. We firmly believe that endothelial cell epigenetics has the potential to become an integral component of precision medicine therapy, unveiling novel therapeutic targets and providing new directions and opportunities for disease treatment.

Graphical Abstract

In recent years, with the deepening of people’s understanding of diseases, angiogenesis has been paid more and more attention. Endothelial cells, as the key cells in angiogenesis, play an important role in the field of angiogenesis research. Glycolysis, lactation, pentose phosphate pathway, amino acid metabolism, non-coding RNA, DNA methylation, histone modification, etc., all have an impact on endothelial cells and thus affect angiogenesis. Endothelial cell epigenetics is expected to become part of precision medicine treatments. Individual treatment plans can be implemented for patients, and precision medicine treatment strategies can be realized. Through epigenetic studies of endothelial cells, new drugs or therapeutic regimens can be developed for clinical application to reduce pain in patients and delay disease progression. Combined with other therapeutic strategies, it can control and guide the formation and reconstruction of blood vessels, and play different roles in different diseases such as diabetes, cardiovascular diseases, and tumors.

Sturtzel C. Endothelial cells. Adv Exp Med Biol. 2017;1003:71–91. https://doi.org/10.1007/978-3-319-57613-8_4.CrossRefPubMed

Wegner M, Pioruńska-Stolzmann M, Jagodziński PP. The impact of chromatin modification on the development of chronic complications in patients with diabetes. Postepy Hig Med Dosw. 2015;69:964–8. https://doi.org/10.5604/17322693.1165198.CrossRef

Katoh M. Therapeutics targeting angiogenesis: genetics and epigenetics, extracellular miRNAs and signaling networks (Review). Int J Mol Med. 2013;32(4):763–7. https://doi.org/10.3892/ijmm.2013.1444.CrossRefPubMedPubMedCentral

Cheng C, Wang Y, Xue Q, Huang Y, Wang X, Liao F, et al. CircRnas in atherosclerosis, with special emphasis on the spongy effect of circRnas on miRnas. Cell Cycle. 2023;22(5):527–41. https://doi.org/10.1080/15384101.2022.2133365.CrossRefPubMed

Mesquita A, Matsuoka M, Lopes SA, Pernambuco FP, Cruz AS, Nader HB, et al. Nitric oxide regulates adhesiveness, invasiveness, and migration of anoikis-resistant endothelial cells. Braz J Med Biol Res. 2022;55:11612. https://doi.org/10.1590/1414-431X2021e11612.CrossRef

Bahadoran Z, Mirmiran P, Kashfi K, Ghasemi A. Vascular nitric oxide resistance in type 2 diabetes. Cell Death Dis. 2023;14(7):410. https://doi.org/10.1038/s41419-023-05935-5.CrossRefPubMedPubMedCentral

Shimokawa H. Reactive oxygen species in cardiovascular health and disease: special references to nitric oxide, hydrogen peroxide, and Rho-kinase. J Clin Biochem Nutri. 2020;66(2):83–91. https://doi.org/10.3164/jcbn.19-119.CrossRef

Dalal PJ, Muller WA, Sullivan DP. Endothelial cell calcium signaling during barrier function and inflammation. Am J Pathol. 2020;190(3):535–42. https://doi.org/10.1016/j.ajpath.2019.11.004.CrossRefPubMedPubMedCentral

Wautier JL, Wautier MP. Vascular permeability in diseases. Int J Mol Sci. 2022;23(7):3645. https://doi.org/10.3390/ijms23073645.CrossRefPubMedPubMedCentral

10.

Dudley AC, Griffioen AW. Pathological angiogenesis: mechanisms and therapeutic strategies. Angiogenesis. 2023;26(3):313–47. https://doi.org/10.1007/s10456-023-09876-7.CrossRefPubMedPubMedCentral

11.

Parmar D, Apte M. Angiopoietin inhibitors: a review on targeting tumor angiogenesis. Eur J Pharmacol. 2021;899:174021. https://doi.org/10.1016/j.ejphar.2021.174021.CrossRefPubMed

12.

Akwii RG, Sajib MS, Zahra FT, Mikelis CM. Role of angiopoietin-2 in vascular physiology and pathophysiology. Cells. 2019;8(5):471. https://doi.org/10.3390/cells8050471.CrossRefPubMedPubMedCentral

13.

Dalton AC, Shlamkovitch T, Papo N, Barton WA. Constitutive association of Tie1 and Tie2 with endothelial integrins is functionally modulated by angiopoietin-1 and fibronectin. PLoS ONE. 2016;11(10):e0163732. https://doi.org/10.1371/journal.pone.0163732.CrossRefPubMedPubMedCentral

14.

Han C, Barakat M, DiPietro LA. Angiogenesis in wound repair: too much of a good thing. Cold Spring Harb Perspect Biol. 2022;14(10):a041225. https://doi.org/10.1101/cshperspect.a041225.CrossRefPubMed

15.

Wu X, Reboll MR, Korf-Klingebiel M, Wollert KC. Angiogenesis after acute myocardial infarction. Cardiovasc Res. 2021;117(5):1257–73. https://doi.org/10.1093/cvr/cvaa287.CrossRefPubMed

16.

Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci: CMLS. 2020;77(9):1745–70. https://doi.org/10.1007/s00018-019-03351-7.CrossRefPubMed

17.

Vimalraj S. A concise review of VEGF, PDGF, FGF, Notch, angiopoietin, and HGF signalling in tumor angiogenesis with a focus on alternative approaches and future directions. Int J Biol Macromol. 2022;221:1428–38. https://doi.org/10.1016/j.ijbiomac.2022.09.129.CrossRefPubMed

18.

Kaštelan S, Orešković I, Bišćan F, Kaštelan H, Gverović AA. Inflammatory and angiogenic biomarkers in diabetic retinopathy. Biochemia Medica. 2020;30(3):030502. https://doi.org/10.11613/BM.2020.030502.CrossRefPubMedPubMedCentral

19.

Li Y. Modern epigenetics methods in biological research. Methods. 2021;187:104–13. https://doi.org/10.1016/j.ymeth.2020.06.022.CrossRefPubMed

20.

Peixoto P, Cartron PF, Serandour AA, Hervouet E. From 1957 to nowadays: a brief history of epigenetics. Int J Mol Sci. 2020;21(20):7571. https://doi.org/10.3390/ijms21207571.CrossRefPubMedPubMedCentral

21.

Greenberg M, Bourc’his D. The diverse roles of DNA methylation in mammalian development and disease. Nat Rev Mol Cell Biol. 2019;20(10):590–607. https://doi.org/10.1038/s41580-019-0159-6.CrossRefPubMed

22.

Bure IV, Nemtsova MV, Kuznetsova EB. Histone modifications and non-coding RNAs: mutual epigenetic regulation and role in pathogenesis. Int J Mol Sci. 2022;23(10):5801. https://doi.org/10.3390/ijms23105801.CrossRefPubMedPubMedCentral

23.

Li L, Wang M, Ma Q, Ye J, Sun G. Role of glycolysis in the development of atherosclerosis. Am J Physiol Cell Physiol. 2022;323(2):C617–29. https://doi.org/10.1152/ajpcell.00218.2022.CrossRefPubMed

24.

He X, Zeng H, Chen JX. Emerging role of SIRT3 in endothelial metabolism, angiogenesis, and cardiovascular disease. J Cell Physiol. 2019;234(3):2252–65. https://doi.org/10.1002/jcp.27200.CrossRefPubMed

25.

Li X, Sun X, Carmeliet P. Hallmarks of endothelial cell metabolism in health and disease. Cell Metab. 2019;30(3):414–33. https://doi.org/10.1016/j.cmet.2019.08.011.CrossRefPubMed

26.

Kierans SJ, Taylor CT. Regulation of glycolysis by the hypoxia-inducible factor (HIF): implications for cellular physiology. J Physiol. 2021;599(1):23–37. https://doi.org/10.1113/JP280572.CrossRefPubMed

27.

Tirpe AA, Gulei D, Ciortea SM, Crivii C, Berindan-Neagoe I. Hypoxia: overview on hypoxia-mediated mechanisms with a focus on the role of HIF genes. Int J Mol Sci. 2019;20(24):6140. https://doi.org/10.3390/ijms20246140.CrossRefPubMedPubMedCentral

28.

Sirover MA. Pleiotropic effects of moonlighting glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in cancer progression, invasiveness, and metastases. Cancer Metastasis Rev. 2018;37(4):665–76. https://doi.org/10.1007/s10555-018-9764-7.CrossRefPubMed

29.

Chiche J, Ricci JE, Pouysségur J. Tumor hypoxia and metabolism – towards novel anticancer approaches. Ann Endocrinol. 2013;74(2):111–4. https://doi.org/10.1016/j.ando.2013.02.004.CrossRef

30.

Zahra K, Dey T, Ashish MSP, Pandey U. Pyruvate kinase M2 and cancer: the role of PKM2 in promoting tumorigenesis. Front Oncol. 2020;10:159. https://doi.org/10.3389/fonc.2020.00159.CrossRefPubMedPubMedCentral

31.

İlhan M. Non-metabolic functions of pyruvate kinase M2: PKM2 in tumorigenesis and therapy resistance. Neoplasma. 2022;69(4):747–54. https://doi.org/10.4149/neo_2022_220119N77.CrossRefPubMed

32.

Movahed ZG, Yarani R, Mohammadi P, Mansouri K. Sustained oxidative stress instigates differentiation of cancer stem cells into tumor endothelial cells: pentose phosphate pathway, reactive oxygen species and autophagy crosstalk. Biomed Pharmacother. 2021;139:111643. https://doi.org/10.1016/j.biopha.2021.111643.CrossRefPubMed

33.

TeSlaa T, Ralser M, Fan J, Rabinowitz JD. The pentose phosphate pathway in health and disease. Nat Metab. 2023;5(8):1275–89. https://doi.org/10.1038/s42255-023-00863-2.CrossRefPubMed

34.

Ge T, Yang J, Zhou S, Wang Y, Li Y, Tong X. The role of the pentose phosphate pathway in diabetes and cancer. Front Endocrinol. 2020;11:365. https://doi.org/10.3389/fendo.2020.00365.CrossRef

35.

Gao Y, Zhou H, Liu G, Wu J, Yuan Y, Shang A. Tumor microenvironment: lactic acid promotes tumor development. J Immunol Res. 2022;2022:3119375. https://doi.org/10.1155/2022/3119375.CrossRefPubMedPubMedCentral

36.

Kumar VB, Viji RI, Kiran MS, Sudhakaran PR. Endothelial cell response to lactate: implication of PAR modification of VEGF. J Cell Physiol. 2007;211(2):477–85. https://doi.org/10.1002/jcp.20955.CrossRefPubMed

37.

Thakur A, Qiu G, Xu C, Han X, Yang T, Ng SP, et al. Label-free sensing of exosomal MCT1 and CD147 for tracking metabolic reprogramming and malignant progression in glioma. Sci Adv. 2020;6(26):eaaz6119. https://doi.org/10.1126/sciadv.aaz6119.CrossRefPubMedPubMedCentral

38.

Logozzi M, Spugnini E, Mizzoni D, Di Raimo R, Fais S. Extracellular acidity and increased exosome release as key phenotypes of malignant tumors. Cancer Metastasis Rev. 2019;38(1–2):93–101. https://doi.org/10.1007/s10555-019-09783-8.CrossRefPubMed

39.

Nagao A, Kobayashi M, Koyasu S, Chow C, Harada H. HIF-1-dependent reprogramming of glucose metabolic pathway of cancer cells and its therapeutic significance. Int J Mol Sci. 2019;20(2):238. https://doi.org/10.3390/ijms20020238.CrossRefPubMedPubMedCentral

40.

Singh L, Aldosary S, Saeedan AS, Ansari MN, Kaithwas G. Prolyl hydroxylase 2: a promising target to inhibit hypoxia-induced cellular metabolism in cancer cells. Drug Discovery Today. 2018;23(11):1873–82. https://doi.org/10.1016/j.drudis.2018.05.016.CrossRefPubMed

41.

Brown TP, Ganapathy V. Lactate/GPR81 signaling and proton motive force in cancer: role in angiogenesis, immune escape, nutrition, and Warburg phenomenon. Pharmacol Ther. 2020;206:107451. https://doi.org/10.1016/j.pharmthera.2019.107451.CrossRefPubMed

42.

Baltazar F, Afonso J, Costa M, Granja S. Lactate beyond a waste metabolite: metabolic affairs and signaling in malignancy. Front Oncol. 2020;10:231. https://doi.org/10.3389/fonc.2020.00231.CrossRefPubMedPubMedCentral

43.

Micaily I, Roche M, Ibrahim MY, Martinez-Outschoorn U, Mallick AB. Metabolic pathways and targets in chondrosarcoma. Front Oncol. 2021;11:772263. https://doi.org/10.3389/fonc.2021.772263.CrossRefPubMedPubMedCentral

44.

Dunaway LS, Pollock JS. HDAC1: an environmental sensor regulating endothelial function. Cardiovasc Res. 2022;118(8):1885–903. https://doi.org/10.1093/cvr/cvab198.CrossRefPubMed

45.

Huang H, Vandekeere S, Kalucka J, Bierhansl L, Zecchin A, Brüning U, et al. Role of glutamine and interlinked asparagine metabolism in vessel formation. EMBO J. 2017;36(16):2334–52. https://doi.org/10.15252/embj.201695518.CrossRefPubMedPubMedCentral

46.

Payen VL, Mina E, Van Hée VF, Porporato PE, Sonveaux P. Monocarboxylate transporters in cancer. Molecular. Metabolism. 2020;33:48–66. https://doi.org/10.1016/j.molmet.2019.07.006.CrossRef

47.

DeBerardinis RJ, Cheng T. Q’s next: the diverse functions of glutamine in metabolism, cell biology and cancer. Oncogene. 2010;29(3):313–24. https://doi.org/10.1038/onc.2009.358.CrossRefPubMed

48.

Kucharzewska P, Welch JE, Svensson KJ, Belting M. Ornithine decarboxylase and extracellular polyamines regulate microvascular sprouting and actin cytoskeleton dynamics in endothelial cells. Exp Cell Res. 2010;316(16):2683–91. https://doi.org/10.1016/j.yexcr.2010.05.033.CrossRefPubMed

49.

Matsunaga T, Weihrauch DW, Moniz MC, Tessmer J, Warltier DC, Chilian WM. Angiostatin inhibits coronary angiogenesis during impaired production of nitric oxide. Circulation. 2002;105(18):2185–91. https://doi.org/10.1161/01.cir.0000015856.84385.e9.CrossRefPubMed

50.

Li X, Kumar A, Carmeliet P. Metabolic pathways fueling the endothelial cell drive. Annu Rev Physiol. 2019;81:483–503. https://doi.org/10.1146/annurev-physiol-020518-114731.CrossRefPubMed

51.

Rana T. Influence and implications of the molecular paradigm of nitric oxide underlying inflammatory reactions of the gastrointestinal tract of dog: a major hallmark of inflammatory bowel disease. Inflamm Bowel Dis. 2022;28(8):1280–8. https://doi.org/10.1093/ibd/izac017.CrossRefPubMed

52.

Özdemir BH, Özdemir AA. How exercise affects the development and progression of hepatocellular carcinoma by changing the biomolecular status of the tumor microenvironment. Exp Clin Transplant: Off J Middle East Soc Organ Transplant. 2022. https://doi.org/10.6002/ect.2021.0456.CrossRef

53.

Laukkanen S, Veloso A, Yan C, Oksa L, Alpert EJ, Do D, et al. Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia. Blood. 2022;140(17):1891–906. https://doi.org/10.1182/blood.2021015106.CrossRefPubMedPubMedCentral

54.

Huang JJ, Hsieh JJ. The therapeutic landscape of renal cell carcinoma: from the Dark Age to the Golden Age. Semin Nephrol. 2020;40(1):28–41. https://doi.org/10.1016/j.semnephrol.2019.12.004.CrossRefPubMedPubMedCentral

55.

Aspriţoiu VM, Stoica I, Bleotu C, Diaconu CC. Epigenetic regulation of angiogenesis in development and tumors progression: potential implications for cancer treatment. Front Cell Dev Biol. 2021;9:689962. https://doi.org/10.3389/fcell.2021.689962.CrossRefPubMedPubMedCentral

56.

Xie Z, Zhou Z, Yang S, Zhang S, Shao B. Epigenetic regulation and therapeutic targets in the tumor microenvironment. Mol Biomed. 2023;4(1):17. https://doi.org/10.1186/s43556-023-00126-2.CrossRefPubMedPubMedCentral

57.

Kulis M, Esteller M. DNA methylation and cancer. Adv Genet. 2010;70:27–56. https://doi.org/10.1016/B978-0-12-380866-0.60002-2.CrossRefPubMed

58.

Gaur P, Hunt CR, Pandita TK. Emerging therapeutic targets in esophageal adenocarcinoma. Oncotarget. 2016;7(30):48644–55. https://doi.org/10.18632/oncotarget.8777.CrossRefPubMedPubMedCentral

59.

Kaz AM, Grady WM. Epigenetic biomarkers in esophageal cancer. Cancer Lett. 2014;342(2):193–9. https://doi.org/10.1016/j.canlet.2012.02.036.CrossRefPubMed

60.

Das D, Karthik N, Taneja R. Crosstalk between inflammatory signaling and methylation in cancer. Front Cell Dev Biol. 2021;9:756458. https://doi.org/10.3389/fcell.2021.756458.CrossRefPubMedPubMedCentral

61.

Mohammed FH, Cemic F, Hemberger J, Giri S. Biological skin regeneration using epigenetic targets. Drug Discovery Today. 2023;28(4):103495. https://doi.org/10.1016/j.drudis.2023.103495.CrossRefPubMed

62.

Bhat SM, Prasad PR, Joshi MB. Novel insights into DNA methylation-based epigenetic regulation of breast tumor angiogenesis. Int Rev Cell Mol Biol. 2023;380:63–96. https://doi.org/10.1016/bs.ircmb.2023.04.002.CrossRefPubMed

63.

Dubey R, Prabhakar PK, Gupta J. Epigenetics: key to improve delayed wound healing in type 2 diabetes. Mol Cell Biochem. 2022;477(2):371–83. https://doi.org/10.1007/s11010-021-04285-0.CrossRefPubMed

64.

Su W, Huo Q, Wu H, Wang L, Ding X, Liang L, et al. The function of LncRNA-H19 in cardiac hypertrophy. Cell Biosci. 2021;11(1):153. https://doi.org/10.1186/s13578-021-00668-4.CrossRefPubMedPubMedCentral

65.

Voellenkle C, Garcia-Manteiga JM, Pedrotti S, Perfetti A, De Toma I, Da Silva D, et al. Implication of Long noncoding RNAs in the endothelial cell response to hypoxia revealed by RNA-sequencing. Sci Rep. 2016;6:24141. https://doi.org/10.1038/srep24141.CrossRefPubMedPubMedCentral

66.

Zhu A, Chu L, Ma Q, Li Y. Long non-coding RNA H19 down-regulates miR-181a to facilitate endothelial angiogenic function. Artif Cells, Nanomed Biotechnol. 2019;47(1):2698–705. https://doi.org/10.1080/21691401.2019.1634577.CrossRefPubMed

67.

Shi X, Wei YT, Li H, Jiang T, Zheng XL, Yin K, et al. Long non-coding RNA H19 in atherosclerosis: what role. Mol Med. 2020;26(1):72. https://doi.org/10.1186/s10020-020-00196-w.CrossRefPubMedPubMedCentral

68.

Zhang Y, Yang M, Yang S, Hong F. Role of noncoding RNAs and untranslated regions in cancer: a review. Medicine. 2022;101(33):e30045. https://doi.org/10.1097/MD.0000000000030045.CrossRefPubMedPubMedCentral

69.

Li ZX, Zhu QN, Zhang HB, Hu Y, Wang G, Zhu YS. MALAT1: a potential biomarker in cancer. Cancer Manag Res. 2018;10:6757–68. https://doi.org/10.2147/CMAR.S169406.CrossRefPubMedPubMedCentral

70.

Braga EA, Fridman MV, Burdennyy AM, Filippova EA, Loginov VI, Pronina IV, et al. Regulation of the key epithelial cancer suppressor miR-124 function by competing endogenous RNAs. Int J Mol Sci. 2022;23(21):13620. https://doi.org/10.3390/ijms232113620.CrossRefPubMedPubMedCentral

71.

He B, Peng F, Li W, Jiang Y. Interaction of lncRNA-MALAT1 and miR-124 regulates HBx-induced cancer stem cell properties in HepG2 through PI3K/Akt signaling. J Cell Biochem. 2019;120(3):2908–18. https://doi.org/10.1002/jcb.26823.CrossRefPubMed

72.

Du M, Chen W, Zhang W, Tian XK, Wang T, Wu J, et al. TGF-β regulates the ERK/MAPK pathway independent of the SMAD pathway by repressing miRNA-124 to increase MALAT1 expression in nasopharyngeal carcinoma. Biomed Pharmacother. 2018;99:688–96. https://doi.org/10.1016/j.biopha.2018.01.120.CrossRefPubMed

73.

Al-Rugeebah A, Alanazi M, Parine NR. MEG3: an oncogenic long non-coding RNA in different cancers. Pathol Oncol Res: POR. 2019;25(3):859–74. https://doi.org/10.1007/s12253-019-00614-3.CrossRefPubMed

74.

Zhang L, Zhao F, Li W, Song G, Kasim V, Wu S. The biological roles and molecular mechanisms of long non-coding RNA MEG3 in the hallmarks of cancer. Cancers. 2022;14(24):6032. https://doi.org/10.3390/cancers14246032.CrossRefPubMedPubMedCentral

75.

Zhao Y, Liu Y, Zhang Q, Liu H, Xu J. The mechanism underlying the regulation of long non-coding RNA MEG3 in cerebral ischemic stroke. Cell Mol Neurobiol. 2023;43(1):69–78. https://doi.org/10.1007/s10571-021-01176-2.CrossRefPubMed

76.

Yang QY, Yu Q, Zeng WY, Zeng M, Zhang XL, Zhang YL, et al. Killing two birds with one stone: miR-126 involvement in both cancer and atherosclerosis. Eur Rev Med Pharmacol Sci. 2022;26(17):6145–68. https://doi.org/10.26355/eurrev_202209_29632.CrossRefPubMed

77.

Soofiyani SR, Hosseini K, Ebrahimi T, Forouhandeh H, Sadeghi M, Beirami SM, et al. Prognostic value and biological role of miR-126 in breast cancer. MicroRNA (Shariqah, United Arab Emirates). 2022;11(2):95–103. https://doi.org/10.2174/1876402914666220428123203.CrossRefPubMed

78.

Tirpe A, Gulei D, Tirpe GR, Nutu A, Irimie A, Campomenosi P, et al. Beyond conventional: the new horizon of anti-angiogenic microRNAs in non-small cell lung cancer therapy. Int J Mol Sci. 2020;21(21):8002. https://doi.org/10.3390/ijms21218002.CrossRefPubMedPubMedCentral

79.

Xie J, Wu W, Zheng L, Lin X, Tai Y, Wang Y, et al. Roles of microRNA-21 in skin wound healing: a comprehensive review. Front Pharmacol. 2022;13:828627. https://doi.org/10.3389/fphar.2022.828627.CrossRefPubMedPubMedCentral

80.

Maryam M, Naemi M, Hasani SS. A comprehensive review on oncogenic miRNAs in breast cancer. J Gen. 2021;100:15.CrossRef

81.

Amini S, Abak A, Sakhinia E, Abhari A. MicroRNA-221 and microRNA-222 in common human cancers: expression, function, and triggering of tumor progression as a key modulator. Lab Med. 2019;50(4):333–47. https://doi.org/10.1093/labmed/lmz002.CrossRefPubMed

82.

Di Martino MT, Arbitrio M, Caracciolo D, Cordua A, Cuomo O, Grillone K, et al. miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: a systematic review. Mol Ther Nucleic Acids. 2022;27:1191–224. https://doi.org/10.1016/j.omtn.2022.02.005.CrossRefPubMedPubMedCentral

83.

Li G, Tian Y, Zhu WG. The roles of histone deacetylases and their inhibitors in cancer therapy. Front Cell Dev Biol. 2020;8:576946. https://doi.org/10.3389/fcell.2020.576946.CrossRefPubMedPubMedCentral

84.

Hai R, Yang D, Zheng F, Wang W, Han X, Bode AM, et al. The emerging roles of HDACs and their therapeutic implications in cancer. Eur J Pharmacol. 2022;931:175216. https://doi.org/10.1016/j.ejphar.2022.175216.CrossRefPubMed

85.

Qiu X, Zhu L, Wang H, Tan Y, Yang Z, Yang L, et al. From natural products to HDAC inhibitors: an overview of drug discovery and design strategy. Bioorg Med Chem. 2021;52:116510. https://doi.org/10.1016/j.bmc.2021.116510.CrossRefPubMed

86.

Wasik A, Ratajczak-Wielgomas K, Badzinski A, Dziegiel P, Podhorska-Okolow M. The role of periostin in angiogenesis and lymphangiogenesis in tumors. Cancers. 2022;14(17):4225. https://doi.org/10.3390/cancers14174225.CrossRefPubMedPubMedCentral

87.

Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y, Hu LL. ERK/MAPK signalling pathway and tumorigenesis. Exp Ther Med. 2020;19(3):1997–2007. https://doi.org/10.3892/etm.2020.8454.CrossRefPubMedPubMedCentral

88.

Revathidevi S, Munirajan AK. Akt in cancer: mediator and more. Semin Cancer Biol. 2019;59:80–91. https://doi.org/10.1016/j.semcancer.2019.06.002.CrossRefPubMed

89.

Makkar R, Behl T, Arora S. Role of HDAC inhibitors in diabetes mellitus. Curr Res Transl Med. 2020;68(2):45–50. https://doi.org/10.1016/j.retram.2019.08.001.CrossRefPubMed

90.

Rabellino A, Andreani C, Scaglioni PP. Roles of ubiquitination and SUMOylation in the regulation of angiogenesis. Curr Issues Mol Biol. 2020;35:109–26. https://doi.org/10.21775/cimb.035.109.CrossRefPubMed

91.

Wang M, Jiang X. The significance of SUMOylation of angiogenic factors in cancer progression. Cancer Biol Ther. 2019;20(2):130–7. https://doi.org/10.1080/15384047.2018.1523854.CrossRefPubMed

92.

Ou K, Yu M, Moss NG, Wang YJ, Wang AW, Nguyen SC, et al. Targeted demethylation at the CDKN1C/p57 locus induces human β cell replication. J Clin Investig. 2019;129(1):209–14. https://doi.org/10.1172/JCI99170.CrossRefPubMed

93.

Ling C, Rönn T. Epigenetics in human obesity and type 2 diabetes. Cell Metab. 2019;29(5):1028–44. https://doi.org/10.1016/j.cmet.2019.03.009.CrossRefPubMedPubMedCentral

94.

Crescenti A, Solà R, Valls RM, Caimari A, Del Bas JM, Anguera A, et al. Cocoa consumption alters the global DNA methylation of peripheral leukocytes in humans with cardiovascular disease risk factors: a randomized controlled trial. PLoS ONE. 2013;8(6):e65744. https://doi.org/10.1371/journal.pone.0065744.CrossRefPubMedPubMedCentral

95.

Guay SP, Légaré C, Houde AA, Mathieu P, Bossé Y, Bouchard L. Acetylsalicylic acid, aging and coronary artery disease are associated with ABCA1 DNA methylation in men. Clin Epigenetics. 2014;6(1):14. https://doi.org/10.1186/1868-7083-6-14.CrossRefPubMedPubMedCentral

96.

Arunachalam G, Yao H, Sundar IK, Caito S, Rahman I. SIRT1 regulates oxidant- and cigarette smoke-induced eNOS acetylation in endothelial cells: role of resveratrol. Biochem Biophys Res Commun. 2010;393(1):66–72. https://doi.org/10.1016/j.bbrc.2010.01.080.CrossRefPubMedPubMedCentral

97.

Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V, et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med. 2017;376(1):41–51. https://doi.org/10.1056/NEJMoa1609243.CrossRefPubMed

98.

Zeng J, Zhang J, Sun Y, Wang J, Ren C, Banerjee S, et al. Targeting EZH2 for cancer therapy: from current progress to novel strategies. Eur J Med Chem. 2022;238:114419. https://doi.org/10.1016/j.ejmech.2022.114419.CrossRefPubMed

99.

Guo J, Zheng Q, Peng Y. BET proteins: biological functions and therapeutic interventions. Pharmacol Ther. 2023;243:108354. https://doi.org/10.1016/j.pharmthera.2023.108354.CrossRefPubMed

100.

Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res: MCR. 2007;5(10):981–9. https://doi.org/10.1158/1541-7786.MCR-07-0324.CrossRefPubMed

101.

Quintás-Cardama A, Santos FP, Garcia-Manero G. Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia. 2011;25(2):226–35. https://doi.org/10.1038/leu.2010.276.CrossRefPubMed

102.

Eleutherakis-Papaiakovou E, Kanellias N, Kastritis E, Gavriatopoulou M, Terpos E, Dimopoulos MA. Efficacy of panobinostat for the treatment of multiple myeloma. J Oncol. 2020;2020:7131802. https://doi.org/10.1155/2020/7131802.CrossRefPubMedPubMedCentral

103.

Sawas A, Radeski D, O’Connor OA. Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review. Ther Adv Hematol. 2015;6(4):202–8. https://doi.org/10.1177/2040620715592567.CrossRefPubMedPubMedCentral

Title: Therapeutic Strategies for Angiogenesis Based on Endothelial Cell Epigenetics
Authors: Yue Cai
Lihua Li
Chen Shao
Yiliu Chen
Zhongqun Wang
Publication date: 31-01-2024
Publisher: Springer US
Keyword: Epigenetics
Published in: Journal of Cardiovascular Translational Research
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-024-10485-y

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Therapeutic Strategies for Angiogenesis Based on Endothelial Cell Epigenetics

Abstract

Graphical Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Graphical Abstract

Please log in to get access to this content

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page